Bilgin T, Ozalp S, Yalçin O T, Zorlu G, Vardar M A, Ozerkan K
Department of Obstetrics and Gynecology, Uludağ-Bursa University, Turkey.
Eur J Gynaecol Oncol. 2003;24(2):169-70.
Single agent gemcitabine was used in recurrent epithelial ovarian cancer patients after standard treatment with debulking surgery and platin-paclitaxel based chemotherapy. Response rates and toxicity results were evaluated retrospectively. Gemcitabine was given in 1000 mg/m2 intravenous infusion over 30 minutes at 1, 8, 15 days of every 28 days. Clinical response was evaluated with clinical findings, serum CA 125 levels, and computerized tomography. Twenty-two patients--ten as second-line, 11 as third-line, and one as fourth line--received gemcitabine. Seven patients received six courses, nine cases three, five cases two and one case one course of treatment. There were four (18.2%) partial and two (9.1%) complete responses with an overall response rate of 27.3%. Stable disease was also observed in three more cases. The progression-free interval was found to be a median of three months. Grade 3-4 neutropenia was seen in two (9.1%) and grade 3-4 thrombocytopenia was seen in four (18.2%) cases. Pancytopenia was observed in one (4.5%) patient. There was no grade 3-4 non-hematological toxicity. Antitumoral activity is encouraging in heavily pretreated ovarian cancer patients. A short progression-free interval is noticeable in responding cases. Toxicity is mainly hematologic and moderate.
对于接受过减瘤手术及以铂类-紫杉醇为基础的化疗等标准治疗后的复发性上皮性卵巢癌患者，采用单药吉西他滨进行治疗。对缓解率和毒性结果进行回顾性评估。吉西他滨以1000 mg/m²的剂量在每28天周期的第1、8、15天静脉输注30分钟。通过临床检查结果、血清CA 125水平及计算机断层扫描来评估临床反应。22例患者接受了吉西他滨治疗，其中10例为二线治疗，11例为三线治疗，1例为四线治疗。7例患者接受了6个疗程的治疗，9例接受了3个疗程，5例接受了2个疗程，1例接受了1个疗程的治疗。有4例（18.2%）部分缓解，2例（9.1%）完全缓解，总缓解率为27.3%。另外还有3例病情稳定。无进展生存期的中位数为3个月。2例（9.1%）出现3-4级中性粒细胞减少，4例（18.2%）出现3-4级血小板减少。1例（4.5%）患者出现全血细胞减少。未观察到3-4级非血液学毒性。对于预处理严重的卵巢癌患者，抗肿瘤活性令人鼓舞。在有反应的病例中，无进展生存期较短较为明显。毒性主要为血液学毒性且程度中等。
